Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation

Cen Yan, Xiaojuan Ma, Sin Man Lam, Yuejie Zhang, Yu Cao, Yuan Dong, Su Li, Guanghou Shui, Yingmei FengJournal of Molecular Cell Biology 2023 · DOI

TL;DR

This study reveals that Exendin-4, a GLP-1 receptor agonist, can slow down atherosclerosis progression by directly inhibiting the proliferation of hematopoietic stem/progenitor cells (HSPCs). This is significant because it suggests a novel mechanism beyond glycemic control for GLP-1 RAs in cardiovascular disease prevention, specifically by rebalancing the immune cell production that contributes to plaque buildup.

What Problem Does This Paper Address?

Atherosclerosis, a major driver of cardiovascular disease, is closely linked to type 2 diabetes. While GLP-1 receptor agonists (GLP-1 RAs) are established anti-diabetic drugs that also show promise in reducing atherosclerosis, their precise mechanisms of action, particularly concerning the immune system, are not fully understood. Specifically, it was unclear whether these drugs influence hematopoietic stem/progenitor cells (HSPCs) – the cells responsible for generating all blood cell types – and if this modulation plays a role in preventing the skewed production of myeloid cells (a process called myelopoiesis) that is implicated in atherosclerosis development, especially in the context of high cholesterol.

Methods

The researchers employed a multi-pronged approach:

  • GLP-1r Expression Analysis: They used capillary western blotting to confirm the presence of the GLP-1 receptor (GLP-1r) on HSPCs.
  • Bone Marrow Transplantation: To assess the role of GLP-1r in HSPCs, they transplanted bone marrow cells (BMCs) from wild-type or GLP-1r knockout mice into lethally irradiated mice with a genetic predisposition to atherosclerosis (LDLr-/- mice) on a high-fat diet (HFD). Chimerism analysis (tracking the origin of blood cells) was performed using FACS.
  • In Vivo Exendin-4 Treatment: LDLr-/- mice were fed an HFD and then treated with either saline or Exendin-4 (Ex-4) for several weeks. Atherosclerotic plaque progression was assessed, along with HSPC frequency, cell cycle, and metabolic profiles.
  • In Vitro Studies: FACS-purified HSPCs were cultured with or without LDL (a key component in atherosclerosis) and Ex-4 to observe effects on cell expansion and differentiation.
  • Targeted Metabolomics: Intracellular metabolite levels in HSPCs were quantified to understand how Ex-4 treatment impacts cellular metabolism.
  • Enzyme Activity Assays: The activity of enzymes involved in glycolysis and gluconeogenesis was measured in liver and BMCs.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from mouse models and in vitro cell cultures.

Key Insights and Ideas

  • HSPCs Express GLP-1r: A crucial finding is that HSPCs themselves express the GLP-1 receptor, suggesting they are direct targets of GLP-1 RAs.
  • GLP-1r Deficiency Skews Myelopoiesis: Mice lacking GLP-1r in their bone marrow showed an imbalance in blood cell production (skewed myelopoiesis) when exposed to high cholesterol, contributing to atherosclerosis.
  • Exendin-4 Directly Inhibits HSPC Proliferation: Ex-4 treatment, both in vitro and in vivo, was shown to suppress the excessive proliferation of HSPCs and the production of granulocytes (a type of myeloid cell) that is exacerbated by high LDL levels.
  • Metabolic Reprogramming by Exendin-4: Ex-4 treatment altered the metabolic landscape of HSPCs, specifically reducing key intermediates in glycolysis and the TCA cycle (like phosphoenolpyruvate and α-ketoglutarate) that are elevated in HFD-fed mice. This suggests Ex-4 influences energy metabolism within these stem cells.
  • Novel Mechanism for Atherosclerosis Prevention: The study proposes that Ex-4's beneficial effects on atherosclerosis are, at least in part, mediated by its direct action on HSPCs, dampening the inflammatory myeloid cell response that drives plaque development.

Key Results

  • Reduced Atherosclerotic Plaque: Ex-4 treatment significantly reduced plaque size in the aorta of hypercholesterolemic mice by 40% and decreased the number of α-SMA+ and CD68+ cells within the plaque.
  • Inhibited HSPC Proliferation: Ex-4 treatment significantly reduced the increased frequency of HSPCs and myeloid progenitors (CMPs and GMPs) observed in mice on a high-fat diet. It also reduced the percentage of BrdU-incorporating (proliferating) HSPCs.
  • Suppressed In Vitro Myeloid Production: In vitro, Ex-4 treatment of HSPCs exposed to LDL reduced cell expansion and the production of F4/80+ macrophages and Gr-1+ granulocytes.
  • Metabolic Changes: Targeted metabolomics revealed that Ex-4 treatment in HFD-fed mice led to decreased intracellular levels of phosphoenolpyruvate (PEP) and α-ketoglutarate in HSPCs.
  • No Effect on Plasma Lipids: Notably, Ex-4 treatment did not alter plasma cholesterol or triglyceride levels in the LDLr-/- mice, suggesting its anti-atherosclerotic effects are independent of direct lipid-lowering actions in this context.

Limitations and Future Work

The authors acknowledge several limitations:

  • In Vitro vs. In Vivo Relevance: While differential metabolite levels were identified in HSPCs, further studies are needed to confirm their specific effects on HSPC function both in vitro and in vivo.
  • GLP-1 Analog Diversity: The study focused on Exendin-4. Given the existence of multiple GLP-1 analogs, future work should investigate if they exhibit similar potencies in regulating HSPCs.
  • HSPC Quiescence: HSPCs are small and quiescent, making the exploration of downstream signaling pathways challenging.
  • FFA Impact: The detection of increased free fatty acids (FFAs) in HFD-fed HSPCs warrants further investigation into their role in oxidative stress and potential contribution to HSPC expansion.

Future directions suggested include exploring the precise signaling pathways downstream of GLP-1/GLP-1r in HSPCs and investigating the impact of various GLP-1 analogs on HSPC regulation. The authors also suggest that altered lipids might enhance oxidative stress and ROS production, contributing to HSPC expansion, which could be a target for future research.

Summary updated

Abstract

Beyond glycemic control, applications of glucagon-like peptide-1 receptor (GLP-1r) agonists (GLP-1 RAs) inhibit inflammation and plaque development in murine atherosclerotic models. However, whether they modulate hematopoietic stem/progenitor cells (HSPCs) to prohibit skewed myelopoiesis in hypercholesteremia remains unknown. In this study, GLP-1r expression in fluorescence-activated cell sorting (FACS)-sorted wild-type HSPCs was determined by capillary western blotting. Bone marrow cells (BMCs) of wild-type or GLP-1r-/- mice were transplanted into lethally irradiated low-density lipoprotein receptor deficient (LDLr-/-) recipients followed by high-fat diet (HFD) for chimerism analysis by FACS. In parallel, LDLr-/- mice were placed on HFD for 6 weeks and then treated with saline or Exendin-4 (Ex-4) for another 6 weeks. HSPC frequency and cell cycle were analyzed by FACS, and intracellular metabolite levels were assessed by targeted metabolomics. The results demonstrated that HSPCs expressed GLP-1r and transplantation of GLP-1r-/- BMCs resulted in skewed myelopoiesis in hypercholesterolemic LDLr-/- recipients. In vitro, Ex-4 treatment of FACS-purified HSPCs suppressed cell expansion and granulocyte production induced by LDL. In vivo, Ex-4 treatment inhibited plaque progression, suppressed HSPC proliferation, and modified glycolytic and lipid metabolism in HSPCs of hypercholesteremic LDLr-/- mice. In conclusion, Ex-4 could directly inhibit HSPC proliferation induced by hypercholesteremia.
BibTeX
@article{yan2023exendin,
  author = {Cen Yan and Xiaojuan Ma and Sin Man Lam and Yuejie Zhang and Yu Cao and Yuan Dong and Su Li and Guanghou Shui and Yingmei Feng},
  title = {{Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation}},
  journal = {Journal of Molecular Cell Biology},
  year = {2023},
  doi = {10.1093/jmcb/mjad014},
}
Figure